4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphoblastic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015255:Idarubicin; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects
D015255:Idarubicin; D003630:Daunorubicin